INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology

ACS Medicinal Chemistry Letters

Volumn 8, Issue 5, 2017, Pages 486-491

  Yue, Eddy W ^a   Sparks, Richard ^a   Polam, Padmaja ^a   Modi, Dilip ^a   Douty, Brent ^a   Wayland, Brian ^a   Glass, Brian ^a   Takvorian, Amy ^a   Glenn, Joseph ^a   Zhu, Wenyu ^a   Bower, Michael ^a   Liu, Xiangdong ^a   Leffet, Lynn ^a   Wang, Qian ^a   Bowman, Kevin J ^a   Hansbury, Michael J ^a   Wei, Min ^a   Li, Yanlong ^a   Wynn, Richard ^a   Burn, Timothy C ^a   Koblish, Holly K ^a   Fridman, Jordan S ^a   Emm, Tom ^a   Scherle, Peggy A ^a   Metcalf, Brian ^a   Combs, Andrew P ^a   more..

^a Drug Metabolism Pharmacokinetics Clinical Pharmacology   (United States)

Author keywords

data centric medicinal chemistry; Epacadostat; IDO1; immuno oncology; INCB24360

Indexed keywords

EPACADOSTAT; KYNURENINE;

AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNOLOGY; CANCER INHIBITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; FEMALE; HUMAN; HUMAN CELL; HYDROGEN BOND; IC50; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 85018003956     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.6b00391     Document Type: Article

References (37)

1. Hodi, F. S.; O’Day, S. J.; McDermott, D. F.; Weber, R. W.; Sosman, J. A.; Haanen, J. B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J. C.; Akerley, W.; van den Eertwegh, A. J. M.; Lutzky, J.; Lorigan, P.; Vaubel, J. M.; Linette, G. P.; Hogg, D.; Ottensmeier, C. H.; Lebbe, C.; Peschel, C.; Quirt, I.; Clark, J. I.; Wolchok, J. D.; Weber, J. S.; Tian, J.; Yellin, M. J.; Nichol, G. M.; Hoos, A.; Urba, W. J. Improved survival with ipilimumab in patients with metastatic melanoma N. Engl. J. Med. 2010, 363, 711-723 10.1056/NEJMoa1003466
2. Robert, C.; Schachter, J.; Long, G. V.; Arance, A.; Grob, J. J.; Mortier, L.; Daud, A.; Carlino, M. S.; McNeil, C.; Lotem, M.; Larkin, J.; Lorigan, P.; Neyns, B.; Blank, C. U.; Hamid, O.; Mateus, C.; Shapira-Frommer, R.; Kosh, M.; Zhou, H.; Ibrahim, N.; Ebbinghaus, S.; Ribas, A. Pembrolizumab versus ipilimumab in advanced melanoma N. Engl. J. Med. 2015, 372, 2521-2532 10.1056/NEJMoa1503093
3. Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J. J.; Cowey, C. L.; Lao, C. D.; Schadendorf, D.; Dummer, R.; Smylie, M.; Rutkowski, P.; Ferrucci, P. F.; Hill, A.; Wagstaff, J.; Carlino, M. S.; Haanen, J. B.; Maio, M.; Marquez-Rodas, I.; McArthur, G. A.; Ascierto, P. A.; Long, G. V.; Callahan, M. K.; Postow, M. A.; Grossmann, K.; Sznol, M.; Dreno, B.; Bastholt, L.; Yang, A.; Rollin, L. M.; Horak, C.; Hodi, F. S.; Wolchok, J. D. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N. Engl. J. Med. 2015, 373, 23-34 10.1056/NEJMoa1504030
4. Weinmann, H. Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators ChemMedChem 2016, 11, 1576 10.1002/cmdc.201600319
5. Adams, J. L.; Smothers, J.; Srinivasan, R.; Hoos, A. Big opportunities for small molecules in immuno-oncology Nat. Rev. Drug Discovery 2015, 14, 603-622 10.1038/nrd4596
6. Melero, I.; Berman, D. M.; Aznar, M. A.; Korman, A. J.; Gracia, J. L. P.; Haanen, J. Evolving synergistic combinations of targeted immunotherapies to combat cancer Nat. Rev. Cancer 2015, 15, 457-472 10.1038/nrc3973
7. Antonia, S. J.; Larkin, J.; Ascierto, P. A. Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects Clin. Cancer Res. 2014, 20, 6258-6268 10.1158/1078-0432.CCR-14-1457
8. Munn, D. H.; Zhou, M.; Attwood, J. T.; Bondarev, I.; Conway, S. J.; Marshall, B.; Brown, C.; Mellor, A. L. Prevention of allogeneic fetal rejection by tryptophan catabolism Science 1998, 281, 1191-1193 10.1126/science.281.5380.1191
9. Munn, D. H.; Mellor, A. L. IDO and tolerance to tumors Trends Mol. Med. 2004, 10 ( 1 ) 15-18 10.1016/j.molmed.2003.11.003
10. Uyttenhove, C.; Pilotte, L.; Theate, I.; Stroobant, V.; Colau, D.; Parmentier, N.; Boon, T.; Van den Eynde, B. J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase Nat. Med. 2003, 9, 1269-1274 10.1038/nm934
11. Zheng, X.; Koropatnick, J.; Li, M.; Zhang, X.; Ling, F.; Ren, X.; Hao, X.; Sun, H.; Vladau, C.; Franek, J. A.; Feng, B.; Urquhart, B. L.; Zhong, R.; Freeman, D. J.; Garcia, B.; Min, W.-P. Reinstalling Antitumor Immunity by Inhibiting Tumor-Derived Immunosuppressive Molecule IDO through RNA Interference J. Immunol. 2006, 177 ( 8 ) 5639-5646 10.4049/jimmunol.177.8.5639
12. Muller, A. J.; DuHadaway, J. B.; Chang, M. Y.; Ramalingam, A.; Sutanto-Ward, E.; Boulden, J.; Soler, A. P.; Mandik-Nayak, L.; Gilmour, S. K.; Prendergast, G. C. Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion Cancer Immunol. Immunother. 2010, 59, 1655-1663 10.1007/s00262-010-0891-4
13. Baban, B.; Chandler, P.; McCool, D.; Marshall, B.; Munn, D. H.; Mellor, A. L. Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific J. Reprod. Immunol. 2004, 61 ( 2 ) 67-77 10.1016/j.jri.2003.11.003
14. Hou, D.-Y.; Muller, A. J.; Sharma, M. D.; DuHadaway, J.; Banerjee, T.; Johnson, M.; Mellor, A. L.; Prendergast, G. C.; Munn, D. H. Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses Cancer Res. 2007, 67 ( 2 ) 792-801 10.1158/0008-5472.CAN-06-2925
15. Yue, E. W.; Douty, B.; Wayland, B.; Bower, M.; Liu, X.; Leffet, L.; Wang, Q.; Bowman, K. J.; Hansbury, M. J.; Liu, C.; Wei, M.; Li, Y.; Wynn, R.; Burn, T. C.; Koblish, H. K.; Fridman, J. S.; Metcalf, B.; Scherle, P. A.; Combs, A. P. Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model J. Med. Chem. 2009, 52, 7364-7367 10.1021/jm900518f
16. Liu, X.; Newton, R. C.; Friedman, S. M.; Scherle, P. A. Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy Curr. Cancer Drug Targets 2009, 9, 938-952 10.2174/156800909790192374
17. Holmgaard, R. B.; Zamarin, D.; Munn, D. H.; Wolchok, J. D.; Allison, J. P. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 J. Exp. Med. 2013, 210, 1389-1402 10.1084/jem.20130066
18. Spranger, S.; Horton, B.; Koblish, H. K.; Scherle, P. A.; Newton, R.; Gajewski, T. F. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment J. Immunother. Cancer 2014, 2, 3 10.1186/2051-1426-2-3
19. Munn, D. H.; Mellor, A. L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance J. Clin. Invest. 2007, 117 ( 5 ) 1147-1154 10.1172/JCI31178
20. Takikawa, O. Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism Biochem. Biophys. Res. Commun. 2005, 338 ( 1 ) 12-19 10.1016/j.bbrc.2005.09.032
21. Metz, R.; DuHadaway, J. B.; Kamasani, U.; Laury-Kleintop, L.; Muller, A. J.; Prendergast, G. C. Novel Tryptophan Catabolic Enzyme IDO2 Is the Preferred Biochemical Target of the Antitumor Indoleamine 2,3-Dioxygenase Inhibitory Compound D-1-Methyl-Tryptophan Cancer Res. 2007, 67 ( 15 ) 7082-7087 10.1158/0008-5472.CAN-07-1872
22. Fatokun, A. A.; Hunt, N. H.; Ball, H. J. Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease Amino Acids 2013, 45, 1319-1329 10.1007/s00726-013-1602-1
23. Prendergast, G. C.; Metz, R.; Muller, A. J.; Mandik-Nayak, L.; Merlo, L. M. F. IDO2 in Immunomodulation and Autoimmune Disease Front. Immunol. 2014, 5, 585 10.3389/fimmu.2014.00585
24. Ball, H. J.; Yuasa, H. J.; Austin, C. J. D.; Weiser, S.; Hunt, N. H. Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway Int. J. Biochem. Cell Biol. 2009, 41 ( 3 ) 467-471 10.1016/j.biocel.2008.01.005
25. Pilotte, L.; Larrieu, P.; Stroobant, V.; Colau, D.; Dolusic, E.; Frederick, R.; De Plaen, E.; Uyttenhove, C.; Wouters, J.; Masereel, B.; Vand den Eynde, B. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 2497-2502 S2497/1-S2497/7 10.1073/pnas.1113873109
26. For a review of recent IDO1 inhibitors: Qian, S.; Zhang, M.; Chen, Q.; He, Y.; Wang, W.; Wang, Z. IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery RSC Adv. 2016, 6, 7575-7581 10.1039/C5RA25046C
27. Obach, R. S.; Baxter, J. G.; Liston, T. E.; Silber, B. M.; Jones, B. C.; Macintyre, F.; Rance, D. J.; Wastall, P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data Journal of Pharmacology and Experimental Therapeutics 1997, 283, 46-58
28. Li, P.; Wang, G.-J.; Li, J.; Zhang, Q.; Liu, X.; Khlentzos, A.; Roberts, M. S. The prediction of the hepatic clearance of tanshinone IIA in rat liver subcellular fractions: accuracy improvement Curr. Drug Metab. 2008, 9, 39-45 10.2174/138920008783331103
29. Froehlich, A. K.; Girreser, U.; Clement, B. Metabolism of benzamidoxime (N-hydroxyamidine) in human hepatocytes and role of UDP-glucuronosyltransferases Xenobiotica 2005, 35, 17-25 10.1080/00498250400021895
30. Boulton, A. J.; Katritzky, A. R. N-Oxides and related compounds. XXII. The rearrangement of 4-nitrobenzofuroxan to 7-nitrobenzofuroxan Rev. Chim., Acad. Rep. Populaire Roumaine 1962, 7, 691-7
31. Liu, X.; Shin, N.; Koblish, H. K.; Yang, G.; Wang, Q.; Wang, K.; Leffet, L.; Hansbury, M. J.; Thomas, B.; Rupar, M.; Waeltz, P.; Bowman, K. J.; Polam, P.; Sparks, R. B.; Yue, E. W.; Li, Y.; Wynn, R.; Fridman, J. S.; Burn, T. C.; Combs, A. P.; Newton, R. C.; Scherle, P. A. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity Blood 2010, 115, 3520-3530 10.1182/blood-2009-09-246124
32. Koblish, H. K.; Hansbury, M. J.; Bowman, K. J.; Yang, G.; Neilan, C. L.; Haley, P. J.; Burn, T. C.; Waeltz, P.; Sparks, R. B.; Yue, E. W.; Combs, A. P.; Scherle, P. A.; Vaddi, K.; Fridman, J. S. Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors Mol. Cancer Ther. 2010, 9, 489-498 10.1158/1535-7163.MCT-09-0628
33. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25 10.1016/S0169-409X(96)00423-1
34. Veber, D. F.; Johnson, S. R.; Cheng, H.-Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates J. Med. Chem. 2002, 45, 2615-2623 10.1021/jm020017n
35. Hopkins, A. L.; Keserue, G. M.; Leeson, P. D.; Rees, D. C.; Reynolds, C. H. The role of ligand efficiency metrics in drug discovery Nat. Rev. Drug Discovery 2014, 13, 105-121 10.1038/nrd4163
36. Gangadhar, T. C.; Hamid, O.; Smith, D. C.; Bauer, T. M.; Waser, J. S.; Luke, J. J.; Balmanoukian, A. S.; Kaufman, D. R.; Zhao, Y.; Maleski, J.; Leopold, L.; Gajewski, T. F. Preliminary results from a phase I/II study of epacadostat (INCB024360) in combination with pembrolizumab in patients with selected advanced cancers J. for ImmunoTherapy of Cancer 2015, 2 ( suppl 2 ) 07 10.1186/2051-1426-3-S2-O7
37. NCT02752074: A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma. www.ClincalTrials.gov.